Effect of Baseline or Changes in Adrenergic Activity on Clinical Outcomes in the β-Blocker Evaluation of Survival Trial
Authors:
- M.R. BristowMBM.R. Bristow
- H. Krause-SteinraufHKH. Krause-Steinrauf
- R. NuzzoRNR. Nuzzo
- Cheng-Seng LiangCLCheng-Seng Liang
- J. LindenfeldJLJ. Lindenfeld
- B.D. LowesBLB.D. Lowes
- B. HattlerBHB. Hattler
- W.T. AbrahamWAW.T. Abraham
- L. OlsonLOL. Olson
- S. KruegerSKS. Krueger
- S. Thaneemit-ChenSTS. Thaneemit-Chen
- J.M. HareJHJ.M. Hare
- 14 September 2004
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 110 (11) , 1437-1442
Abstract
Background— Adrenergic activation is thought to be an important determinant of outcome in subjects with chronic heart failure (CHF), but baseline or serial changes in adrenergic activity have not been previously investigated in a large patient sample treated with a powerful antiadrenergic agent. Methods and Results— Systemic venous norepinephrine was measured at baseline, 3 months, and 12 months in the β-Blocker Evaluation of Survival Trial (BEST), which compared placebo treatment with the β-blocker/sympatholytic agent bucindolol. Baseline norepinephrine level was associated with a progressive increase in rates of death or death plus CHF hospitalization that was independent of treatment group. On multivariate analysis, baseline norepinephrine was also a highly significant ( P Conclusions— In BEST, a subset of patients treated with bucindolol had an increased risk of death as the result of sympatholysis, which compromised the efficacy of this third-generation β-blocker.Keywords
This publication has 13 references indexed in Scilit:
- Adverse Mortality Effect of Central Sympathetic Inhibition with Sustained-Release Moxonidine in Patients with Heart Failure (MOXCON)European Journal of Heart Failure, 2003
- Changes in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT)Circulation, 2003
- Effects of Sustained-Release Moxonidine, an Imidazoline Agonist, on Plasma Norepinephrine in Patients With Chronic Heart FailureCirculation, 2002
- A Trial of the Beta-Blocker Bucindolol in Patients with Advanced Chronic Heart FailureNew England Journal of Medicine, 2001
- Altered Beta-adrenergic Receptor Gene Regulation and Signaling in Chronic Heart FailureJournal of Molecular and Cellular Cardiology, 2001
- Prognostic value of neurohormonal activation and cardiopulmonary exercise testing in patients with chronic heart failureThe American Journal of Cardiology, 2000
- Adverse consequences of high sympathetic nervous activity in the failing human heartJACC, 1995
- Long-term predictors of sudden and low output death in chronic congestive heart failure secondary to coronary artery diseaseThe American Journal of Cardiology, 1989
- Plasma Norepinephrine as a Guide to Prognosis in Patients with Chronic Congestive Heart FailureNew England Journal of Medicine, 1984
- Importance of the adrenergic nervous system in the support of circulatory function in patients with congestive heart failureThe American Journal of Medicine, 1963